An immunotherapy for type 1 diabetes has been approved for use in the UK, in a move which could mark a ‘turning point’ in treatment of the condition if eligible patients could be identified. The Medicines and Healthcare products Regulatory Agency (MHRA) said teplizumab, also known as Tzield, is safe and effective at delaying the The post MHRA approves immunotherapy which delays development of type 1 diabetes appeared first on Pulse Today.